Meeting Coverage

EHA

European Hematology Association

Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphoma

ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment

A photo of the packaging and vial of Adcetris over a computer rendering of a Reed-Sternberg cell in Hodgkin lymphoma

Latest EHA Meetings

Fixed-Duration, All-Oral Regimen Slows CLL Progression

Near-80% reduction in PFS hazard with ibrutinib-venetoclax versus obinutuzumab-chlorambucil

June 16, 2021
How CAR T-Cell Therapy Measures Up in Follicular Lymphoma

Better response rates and survival with axicabtagene ciloleucel versus external control group

June 15, 2021
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL

Better overall response rate, less cardiotoxicity, with second-generation BTK inhibitor

June 14, 2021
New Standard for Relapsed/Refractory Multiple Myeloma?

Triplet regimen significantly extended median PFS versus doublet in IKEMA study

June 15, 2020
One Proteasome Inhibitor Tops Another in Relapsed Myeloma

Progression-free survival doubled with carfilzomib versus bortezomib

June 15, 2015
PFS Rises in Progressive Myeloma with Targeted Biologic

Adding elotuzumab boosts median progression-free survival by almost 5 months.

June 12, 2015